DexCom Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
DexCom yıllık ortalama 24.2% oranında kazançlarını artırırken, Medical Equipment sektöründe kazançlar growing at 13.1% annual. Gelirler growing yılda ortalama 20.4% oranında artmaktadır. DexCom'in özkaynak karlılığı 34.4% ve net marjı 17.2%'dir.
Anahtar bilgiler
24.2%
Kazanç büyüme oranı
23.5%
EPS büyüme oranı
Medical Equipment Sektör Büyümesi | 8.9% |
Gelir büyüme oranı | 20.4% |
Özkaynak getirisi | 34.4% |
Net Marj | 17.2% |
Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
DexCom Growing Into Its Valuation, But Still No Bargain
Oct 25DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings
Oct 21DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships
Oct 16These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely
Sep 30DexCom: Investors Discounting Long CGM Growth Runway
Sep 19We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)
Sep 16DexCom Q2 Earnings: Traditional Market Overreaction
Aug 07Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?
Jul 26DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures
Jul 26Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E
Jul 12DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact
Jul 03DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly
Jun 28Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Jun 03Dexcom: Positive Catalysts Ahead To Support Growth
May 13If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity
May 07DexCom: Attractive Discount After Strong Earnings Results
May 06Returns At DexCom (NASDAQ:DXCM) Are On The Way Up
Apr 25Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price
Apr 12DexCom Is Pricey For A Reason - Its Growth Story Reflects That
Apr 11Is DexCom (NASDAQ:DXCM) Using Too Much Debt?
Mar 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Mar 04DexCom: A Wealth Compounder In Healthcare
Feb 14DexCom: Stelo Stellar Outlook
Jan 17DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital
Jan 15DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing
Jan 01DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly
Dec 18A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Dec 05At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?
Nov 21DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital
Sep 28DexCom (NASDAQ:DXCM) Could Easily Take On More Debt
Sep 13Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Aug 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Aug 14DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet
Jun 05There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital
May 16Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?
Mar 21These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely
Mar 03DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price
Feb 13Gelir ve Gider Dağılımı
DexCom nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Sep 24 | 3,954 | 681 | 1,262 | 549 |
30 Jun 24 | 3,935 | 667 | 1,242 | 545 |
31 Mar 24 | 3,802 | 639 | 1,208 | 528 |
31 Dec 23 | 3,622 | 542 | 1,185 | 506 |
30 Sep 23 | 3,403 | 377 | 1,187 | 486 |
30 Jun 23 | 3,198 | 358 | 1,135 | 465 |
31 Mar 23 | 3,023 | 293 | 1,085 | 467 |
31 Dec 22 | 2,910 | 341 | 1,008 | 484 |
30 Sep 22 | 2,793 | 244 | 936 | 605 |
30 Jun 22 | 2,673 | 230 | 900 | 623 |
31 Mar 22 | 2,572 | 258 | 837 | 631 |
31 Dec 21 | 2,449 | 217 | 811 | 604 |
30 Sep 21 | 2,319 | 577 | 749 | 487 |
30 Jun 21 | 2,170 | 562 | 709 | 445 |
31 Mar 21 | 2,027 | 530 | 660 | 396 |
31 Dec 20 | 1,927 | 550 | 618 | 360 |
30 Sep 20 | 1,821 | 231 | 574 | 320 |
30 Jun 20 | 1,716 | 205 | 539 | 299 |
31 Mar 20 | 1,601 | 148 | 541 | 288 |
31 Dec 19 | 1,476 | 101 | 516 | 274 |
30 Sep 19 | 1,351 | -171 | 499 | 252 |
30 Jun 19 | 1,222 | -170 | 479 | 236 |
31 Mar 19 | 1,128 | -130 | 452 | 214 |
31 Dec 18 | 1,032 | -127 | 433 | 417 |
30 Sep 18 | 915 | 43 | 414 | 191 |
30 Jun 18 | 833 | -5 | 393 | 184 |
31 Mar 18 | 761 | -33 | 368 | 182 |
31 Dec 17 | 719 | -50 | 349 | 185 |
30 Sep 17 | 669 | -48 | 336 | 180 |
30 Jun 17 | 633 | -65 | 327 | 181 |
31 Mar 17 | 599 | -88 | 311 | 172 |
31 Dec 16 | 573 | -66 | 286 | 156 |
30 Sep 16 | 533 | -57 | 268 | 141 |
30 Jun 16 | 490 | -80 | 245 | 125 |
31 Mar 16 | 445 | -64 | 221 | 113 |
31 Dec 15 | 402 | -58 | 198 | 101 |
30 Sep 15 | 356 | -58 | 173 | 94 |
30 Jun 15 | 319 | -20 | 155 | 85 |
31 Mar 15 | 285 | -23 | 140 | 76 |
31 Dec 14 | 259 | -22 | 128 | 69 |
30 Sep 14 | 227 | -26 | 116 | 60 |
30 Jun 14 | 201 | -27 | 104 | 52 |
31 Mar 14 | 178 | -31 | 94 | 47 |
31 Dec 13 | 160 | -30 | 84 | 42 |
Kaliteli Kazançlar: DXCM yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: DXCM 'nin mevcut net kar marjları (17.2%) geçen yılın (11.1%) sinden daha yüksektir.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: DXCM son 5 yılda karlı hale geldi ve kazançlarını yıllık 24.2% oranında artırdı.
Büyüme Hızlandırma: DXCM 'un son bir yıldaki kazanç büyümesi ( 80.6% ) 5 yıllık ortalamasını (yıllık 24.2% ) aşıyor.
Kazançlar vs. Sektör: DXCM geçen yılki kazanç büyümesi ( 80.6% ) Medical Equipment sektörünün 12.2% değerini aştı.
Özkaynak Getirisi
Yüksek ROE: DXCM 'nin Özsermaye Getirisi ( 34.4% ) yüksek olsa da, bu ölçüm yüksek borç seviyeleri nedeniyle çarpıktır.